HighVista Strategies »

Tourmaline Bio shares owned by HighVista Strategies

Quarter-by-quarter ownership of Tourmaline Bio (TRML) shares owned by HighVista Strategies from 13F filings

Historical chart of HighVista Strategies investment in Tourmaline Bio

Tip: Access up to 7 years of quarterly data

All positions including Tourmaline Bio held by HighVista Strategies consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Tourmaline Bio by HighVista Strategies

Quarter filed Position value Share count Share price at filing
2024-03-31 $1.2M 53k 22.90

More positions owned by HighVista Strategies

Invesco Db Commdy Indx Trck Unit (DBC)
Apogee Therapeutics (APGE)
Spyre Therapeutics Com New (SYRE)
Merus N V (MRUS)
Microsoft Corporation (MSFT)
Arcellx Common Stock (ACLX)
Xpo Logistics Inc equity (XPO)
Nuvalent Inc-a (NUVL)
Ansys (ANSS)
Hess (HES)
Ideaya Biosciences (IDYA)
Juniper Networks (JNPR)
Sp Plus (SP)
Cerevel Therapeutics Hldng I (CERE)
Albertsons Cos Common Stock (ACI)

View all positions for HighVista Strategies

Top funds holding Tourmaline Bio

Blue Owl Capital Holdings
Cormorant Asset Management
Jennison Associates
QVT Financial
Vanguard Group
Braidwell
venBio Select Advisor
Nantahala Capital Management
Qiming U.S. Ventures Management
Vivo Capital
BlackRock
Darwin Global Management
Eventide Asset Management
Velan Capital Investment Management
Artal Group

View all funds holding Tourmaline Bio